Improving lives through science, compassion, and dedication to rare conditions.
We bring novel treatments to those living with ultra-rare and underserved diseases.
We strive to be a trusted global partner for transformative healthcare solutions.
Focused Innovation in Rare Disease Therapies
Part of Amryt Pharma
Aegerion is a proud member of the Amryt Pharma family – united in purpose, global in impact.
Key Products / Overview
Juxtapid® (lomitapide)
Juxtapid is an oral medication approved for the treatment of HoFH, a rare genetic disorder characterized by extremely high cholesterol levels. The European Commission granted approval for Juxtapid in 2013, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).
Myalept® (metreleptin)
Myalept is the first and only approved therapy for generalized lipodystrophy, a condition marked by the loss of fat tissue and associated metabolic complications. AstraZeneca divested Myalept to Aegerion Pharmaceuticals in 2014, enabling the company to expand its rare disease portfolio
Overview
Aegerion Pharmaceuticals Limited operates primarily in the wholesale distribution of pharmaceutical goods, aligning with Amryt Pharma's mission to address unmet medical needs in rare disease communities. The company's portfolio includes treatments for conditions such as homozygous familial hypercholesterolemia (HoFH) and generalized lipodystrophy.
Frequently asked questions
01. What does Aegerion Pharmaceuticals UK specialize in?
Aegerion Pharmaceuticals UK specializes in the development and commercialization of therapies for rare and ultra-rare diseases, with a focus on lipid and metabolic disorders such as Homozygous Familial Hypercholesterolemia (HoFH) and generalized lipodystrophy.
02. What products does Aegerion Pharmaceuticals UK offer?
Aegerion's UK portfolio includes Juxtapid® (lomitapide) for HoFH and Myalept® (metreleptin) for generalized lipodystrophy. These therapies address critical needs in small patient populations with limited treatment options.
03. Is Aegerion Pharmaceuticals UK part of a larger organization?
Yes. Aegerion Pharmaceuticals UK is a subsidiary of Amryt Pharma, a global biopharmaceutical company focused on rare and orphan diseases. The acquisition in 2019 expanded Amryt’s global reach and product portfolio.
04. How can healthcare professionals access Aegerion’s products?
Healthcare professionals can access Aegerion’s therapies through approved distribution channels. Product-specific medical information, support, and distribution details are available through the company’s medical affairs or market access teams.